Skip to content

Skye Bioscience, Inc.: 10-Q filed 2014-06-05

What Skye Bioscience, Inc. reported in its quarterly report filed 2014-06-05 (fiscal Q2 2014): 23 published measures, 62 facts as tagged in accession 0001557240-14-000313.

This filing

Form
10-Q (quarterly report)
Filed
2014-06-05
Fiscal period
fiscal Q2 2014
Accession
0001557240-14-000313 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Skye Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-04-30122,728USD
At 2013-10-31145,694USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-04-3049,347USD
At 2013-10-3162,317USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-04-3073,381USD
At 2013-10-3183,377USD
At 2012-10-3138,559USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-04-3049,952USD
At 2013-10-3152,186USD
At 2013-04-3029,712USD
At 2012-10-3126,404USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-31 to 2014-04-30-13,514USD90
2013-11-01 to 2014-04-30-9,996USD181
2012-11-01 to 2013-10-31-3,782USD365
2013-01-31 to 2013-04-302,069USD90
2012-11-01 to 2013-04-302,229USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-11-01 to 2013-04-3049,116USD181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-01-31 to 2013-04-301,056USD90
2012-11-01 to 2013-04-301,138USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-04-3034,813USD
At 2013-10-3139,560USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-31 to 2014-04-30-13,431USD90
2013-11-01 to 2014-04-30-14,764USD181
2013-01-31 to 2013-04-303,612USD90
2012-11-01 to 2013-04-30-2,582USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-04-3087,915USD
At 2013-10-31106,134USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-31 to 2014-04-30307USD90
2013-11-01 to 2014-04-30717USD181
2013-01-31 to 2013-04-30649USD90
2012-11-01 to 2013-04-30862USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-04-3049,347USD
At 2013-10-3162,317USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-04-3035,425USD
At 2013-10-3125,338USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-01-31 to 2014-04-3086,271USD90
2013-11-01 to 2014-04-30150,939USD181
2013-01-31 to 2013-04-30105,317USD90
2012-11-01 to 2013-04-30168,641USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-04-303,623,500shares
At 2013-10-313,623,500shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-04-3047,472USD
At 2013-10-3147,472USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-04-3012,659USD
At 2013-10-317,912USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-01-31 to 2014-04-30-13,514USD90
2013-11-01 to 2014-04-30-9,996USD181
2013-01-31 to 2013-04-303,125USD90
2012-11-01 to 2013-04-303,367USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-31 to 2014-04-307,084USD90
2013-11-01 to 2014-04-3015,727USD181
2013-01-31 to 2013-04-307,425USD90
2012-11-01 to 2013-04-3012,511USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-11-01 to 2014-04-304,747USD181
2012-11-01 to 2013-04-304,645USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-31 to 2014-04-30-83USD90
2013-11-01 to 2014-04-304,768USD181
2013-01-31 to 2013-04-30-487USD90
2012-11-01 to 2013-04-305,949USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-11-01 to 2013-04-3024,800USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2013-11-01 to 2014-04-3010,087USD181
2012-11-01 to 2013-04-3025,172USD181

Inspect the source

Entity
Skye Bioscience, Inc. / CIK 0001516551
Captured
2026-09-20T09:13:51.237Z
SEC response SHA-256
fd229875bbe9efbf8ce715b00820b845a594b6e60bad8dd4ff739bde7e7cfc9e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001516551.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))